Recent news on Zileuton

Zileuton Syrup (Zileuton capsule) Information  -  May 20, 2007
American Chronicle,Zileuton medication belong to Leukotriene receptor antagonist reverse transcriptase inhibitor class. Zileuton attenuates bronchoconstriction by inhibiting

Critical Therapeutics signs licensing deal for asthma drug  -  May 22, 2007
ReutersCyDex has been given a worldwide, exclusive license to develop and sell Zileuton combined with or formulated using Captisol, its patented drug enablement

SkyePharma losses widen, but key drug on track  -  26 Apr 2007
Reuters.uk,...to make an operating profit in 2008, thanks to revenue from other new drugs such as arthritis treatment Lodotra and anti-inflammatory drug zileuton.

Critical Therapeutics Announces the Publication of New Preclincial ...  -  Apr 19, 2007
PharmaLive.com (press release),The Company owns worldwide rights to ZYFLO(R) (zileuton tablets), which is marketed in the United States for the prevention and chronic treatment of asthma

Officials from Critical Therapeutics report on recent activities  -  Apr 12, 2007
Therapeutics Daily (subscription) (press release),Report 1: Critical Therapeutics, Inc. (CRTX) announced that preliminary results indicate continued incremental growth in unit sales of Zyflo (zileuton

Revised Product Labeling for Zanaflex  -  Apr 13, 2007
Facts and Comparisons,Based on this data, the coadministration of tizanidine with other CYP1A2 inhibitors (including zileuton, other fluroquinolones, antiarrythmics, cimetidine,

FDA MedWatch: Zanaflex (tizanidine hydrochloride) Tablets and ...  -  Apr 12, 2007
PharmaLive.com (press release),...coadministration of tizanidine with other CYP1A2 inhibitors (zileuton, other fluroquinolones, antiarrythmics, cimetidine, famotidine,

Critical Therapeutics Announces Beckman Coulter Exercises Option ...  -  Feb 13, 2007
Business Wire (press release),The Company owns worldwide rights to ZYFLO® (zileuton tablets), which is marketed in the United States for the prevention and chronic treatment of asthma in

Critical Therapeutics Reports Preliminary Operating Results for ...  -  Jan 9, 2007
Business Wire (press release),In October 2006, the Company announced a restructuring to focus its efforts on the zileuton franchise, including the controlled-release and intravenous

Critical Therapeutics' Board of Directors Appoints Frank Thomas as ...  -  Dec 21, 2006
Genetic Engineering News (press release),The Company owns worldwide rights to ZYFLO(R) (zileuton tablets), which is marketed in the United States for the prevention and chronic treatment of asthma

Reports from Critical Therapeutics present the latest news and ...  -  Dec 21, 2006
Therapeutics Daily (subscription) (press release),Zileuton CR is an investigational drug developed for the prevention and chronic treatment of asthma in adults and children 12 years of age and older.

Health Guide: Asthma and Medications  -  Jan 2, 2007
Market-Day.net,Cromolyn Sodium or NedocromilSodium Inhalers, pills such as Zafirlukast, Zileuton, and Montelukast,Corticosteroids, Theophylline, and Epinephrine shots.

Critical Therapeutics' Board of Directors Appoints Frank Thomas as ...  -  Dec 21, 2006
Genetic Engineering News (press release),The Company owns worldwide rights to ZYFLO(R) (zileuton tablets), which is marketed in the United States for the prevention and chronic treatment of asthma

Reports from Critical Therapeutics present the latest news and ...  -  Dec 21, 2006
Therapeutics Daily (subscription) (press release),Zileuton CR is an investigational drug developed for the prevention and chronic treatment of asthma in adults and children 12 years of age and older.

Critical Therapeutics Announces NIH-Sponsored Study to Investigate ...  -  Dec 15, 2006
PharmaLive.com (press release),Patients who have been admitted to the hospital with acute exacerbations of COPD will be randomized to receive either oral placebo or zileuton (600 mg QID)

Market Report -- In Play (CRTX)  -  Dec 15, 2006
MSN Money...to evaluate whether using ZYFLO (zileuton tablets) to treat patients admitted to the hospital with acute exacerbations of chronic obstructive pulmonary

Critical Therapeutics to Present at the UBS 2006 Global Life ...  Sep 22, 2006
The Company owns worldwide rights to ZYFLO(R) (zileuton tablets), as well as the controlled-release and intravenous formulations of zileuton. ... -PharmaLive.com

Critical Therapeutics Announces Results of CTI-01 Phase II Trial  Sep 15, 2006
...diseases. The Company owns worldwide rights to the asthma drug ZYFLO(R) (zileuton tablets), as well as other formulations of zileuton. ... -Genetic Engineering News

Critical Therapeutics Announces Efficacy Data for Controlled ...  -  Nov 15, 2006
Genetic Engineering News (press release),Two posters highlighted efficacy data for the twice daily, controlled-release formulation of zileuton (zileuton CR). The third poster reviewed data showing

Controlled Release Zileuton Provides Early, Sustained Improvements ...  -  Nov 15, 2006
DG NewsThe results came from a pivotal randomized, placebo-controlled randomized study of zileuton CR 1200 mg twice daily in 613 patients with asthma who were not

Critical Therapeutics Announces Change in Leadership of Specialty ...  Jul 18, 2006
Critical Therapeutics' specialty sales force, which markets its asthma drug, ZYFLO(R) (zileuton tablets), will be led by an internal sales management team ... -Business Wire

Critical Therapeutics Announces Changes to Management Team and ...  Jun 26, 2006
..."Under Paul, the Company completed its initial public offering, commercialized its first drug, ZYFLO(R) (zileuton tablets), and expanded its development ... -Genetic Engineering News

Critical Therapeutics Announces Anne M. Fields to Head Its ...  Jun 30, 2006
...(Nasdaq: CRTX) today announced that Anne M. Fields will lead the specialty sales force that markets its asthma drug, ZYFLO(R) (zileuton tablets). ... -International News Service

Critical Therapeutics CEO Rubin Resigns  Jun 26, 2006
...recent cost-cutting measures, the changes will help the company focus on the upcoming launch of the controlled-release formulation of its zileuton, or Zyflo ... -MSN Money

PEOPLES PHARMACY Potassium deficiency creates serious risk  Jun 26, 2006
...overused. Other asthma medications that ease inflammation include montelukast (Singulair), zafirlukast (Accolate) or zileuton (Zyflo). ... -Houston Chronicle

Critical Therapeutics President, CEO And Director Paul Rubin Steps ...  Jun 26, 2006
President of Finance and Treasurer. Critical Therapeutics said it expects to submit the new drug application for zileuton CR in August. -Trading Markets

Critical Therapeutics Announces Executive Management Changes ...  Jun 26, 2006
Under Paul, the Company completed its initial public offering, commercialized its first drug, ZYFLO-zileuton tablets, and expanded its development pipeline. ... -Trading Markets

SkyePharma Business Review Day 2006  Jun 21, 2006
GlaxoSmithKline's treatment for Parkinson's disease, filed at the end of 2005; a new controlled release formulation of Zyflo® (zileuton), Critical Therapeutics ... -Yahoo! News

SkyePharma Business Review Day 2006  Jun 21, 2006
...treatment for Parkinson's disease, filed at the end of 2005; a new controlled release formulation of Zyflo(R) (zileuton), Critical Therapeutics' oral treatment ... -Drug Newswire



Critical Therapeutics on Target to Submit NDA for Zileuton ...  May 2, 2006
FDA) has accepted the Company's proposal to submit the New Drug Application (NDA) for its controlled-release (CR) formulation of zileuton with six months of ... - Genetic Engineering News

Critical Therapeutics Reports First Quarter 2006 Financial Results ...  May 4, 2006
These reductions should provide additional capital to support the anticipated 2007 launch of the controlled-release (CR) formulation of zileuton. ... - Genetic Engineering News

Critical Therapeutics, FDA Accepts Proposal For Submission Of New ...  May 2, 2006
Administration has accepted the company's proposal to submit the New Drug Application, NDA for its controlled-release or CR formulation of zileuton, a drug ... - Trading Markets

Critical Therapeutics Says FDA Accepts Proposal To Submit NDA For ...  May 2, 2006
...that the US Food and Drug Administration has accepted its proposal to submit the New Drug Application for its controlled-release formulation of zileuton. ... - Trading Markets

Highlights of rising and falling US stocks - UPDATE 2  May 2, 2006
...gained after the Lexington, Mass., firm said its proposal to submit a new drug application for its controlled-release formulation of zileuton was accepted by ... - Euro2day

Critical Therapeutics Announces Schedule of Upcoming Investor ...  Apr 20, 2006
...care diseases. The Company owns worldwide rights to ZYFLO(R) (zileuton tablets), as well as other formulations of zileuton. ZYFLO ... - Genetic Engineering News

Critical Therapeutics to Announce First-Quarter 2006 Financial ...  Apr 20, 2006
...diseases. The Company owns worldwide rights to the asthma drug ZYFLO(R) (zileuton tablets), as well as other formulations of zileuton. ... - PharmaLive.com

SkyePharma PLC - Preliminary Results Announcement for the Year ...  Apr 19, 2006
...in January 2006 that it had initiated two studies designed to support a New Drug Application for a twice-daily version of Zyflo(R) (zileuton), an oral ... - PR Newswire





Mc|K Advertising chosen to promote ZYFLO from Critical ...  Mar 13, 2006
Critical Therapeutics, Inc. of Lexington, MA for the professional marketing and promotion of ZYFLO® (zileuton tablets). ZYFLO was ... - PharmaLive.com

Critical Therapeutics Announces Decision to Discontinue Clinical ...  Mar 15, 2006
...diseases. The Company owns worldwide rights to the asthma drug ZYFLO(R) (zileuton tablets), as well as other formulations of zileuton. ... - Genetic Engineering News



Critical Therapeutics Announces Presentation Schedule for Upcoming ...  Feb 28, 2006
At these events, management will provide an update on the Company's strategy and operations, including the launch of ZYFLO(R) (zileuton tablets), and review ... - PharmaLive.com,

Critical Therapeutics Reports Fourth Quarter and Full Year 2005 ...  Feb 9, 2006
The Company also announced initial sales and prescriptions written for its first commercial product, ZYFLO(R) (zileuton tablets). ... - Genetic Engineering News,

Critical Therapeutics Announces Abstracts Presented at European ...  Feb 17, 2006
...care diseases. The Company owns worldwide rights to ZYFLO(R) (zileuton tablets), as well as other formulations of zileuton. ZYFLO ... - Genetic Engineering News,

Critical Therapeutics Reports Fourth Quarter and Full Year 2005 ...  09 Feb 2006
The Company also announced initial sales and prescriptions written for its first commercial product, ZYFLO(R) (zileuton tablets). ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional